Valuation: NetraMark Holdings Inc.

Market Cap 75.7M 53.9M 46.84M 43.73M 40.15M 5.14B 77.02M 516M 202M 2.56B 202M 198M 8.45B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 75.7M 53.9M 46.84M 43.73M 40.15M 5.14B 77.02M 516M 202M 2.56B 202M 198M 8.45B EV / Sales 2026 *
189x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
07-10 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-30 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-15 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-08 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-10 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
03-25 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
03-25 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
03-25 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 53.96M
+5.36%+25.28%-8.99%+49.23% 3,451B
+2.33%-4.99%-22.21%+567.93% 295B
+3.39%+9.51%+98.24%+157.53% 95.39B
-0.55%-0.81%-7.95%+46.93% 93.64B
+0.42%+0.22%-38.71%-11.43% 74.44B
+3.22%+5.23%-29.92%+77.87% 65.38B
+1.27%+1.77%+9.85%+70.33% 45.42B
+3.49%+1.67%-25.73%-45.02% 30.53B
+0.25%+1.43%+57.40%+218.97% 29.95B
Average +1.70%+6.03%+3.55%+125.82% 464.51B
Weighted average by Cap. +4.05%+18.51%-7.75%+88.38%

Financials

2026 *2027 *
Net sales 401K 285K 248K 232K 213K 27.21M 408K 2.73M 1.07M 13.57M 1.07M 1.05M 44.75M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise